Q3 FY2026 · ended Jun 30, 2026 · Revenue $59,065, +0.0% YoY · Filed Aug 17, 2026
Regen Biopharma, Inc. (RGBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $59,065 and a net loss of $637,785.
Revenue
$59,065
+0.0% vs prior quarter
Net income
$-637,785
-164.3% vs prior quarter
Operating cash flow
$-24,069
+57.0% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
1.68B
+5209.1% vs year-ago quarter
Net cash
—
Operating margin
-339.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RGBP (OTC), RGBPP (OTC)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- La Mesa, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1589150
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q2 FY2025 Mar 31, 2025 |
Q1 FY2025 Dec 31, 2024 |
|---|---|---|---|---|---|
| Revenue | $59,065 | $59,065 | $59,065 | $59,065 | $59,065 |
| Operating income | $24,528 | -$153,709 | -$551,624 | -$113,349 | -$61,378 |
| Net income | -$637,785 | $991,927 | -$967,853 | -$19,354 | -$515,384 |
| Diluted EPS | $0.00 | $0.00 | -$0.01 | $0.00 | -$0.13 |
| Operating cash flow | -$24,069 | -$63,234 | -$197,941 | -$101,230 | -$66,379 |
| Total assets | $287,587 | $260,194 | $237,076 | $169,482 | $191,416 |
| Total liabilities | $6.2M | $5.6M | $6.8M | $5.9M | $5.9M |
| Stockholders' equity | -$5.9M | -$5.4M | -$6.6M | -$5.7M | -$5.7M |
| Cash and investments | $239 | $271 | $4,578 | — | $135 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 2, 2026 | Oct 27, 2026 |
| 10-Q | Quarterly report | Aug 17, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Auditor change, Other events
|
Jul 15, 2026 | Jul 10, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Mar 4, 2026 | Feb 4, 2026 |
| 10-Q | Quarterly report | Feb 13, 2026 | Dec 31, 2025 |
All 263 Regen Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.